Slovenia Country Commercial Guide
Learn about the market conditions, opportunities, regulations, and business conditions in slovenia, prepared by at U.S. Embassies worldwide by Commerce Department, State Department and other U.S. agencies’ professionals
Select Country Guide
Pharmaceuticals
Last published date:

Overview

Slovenia’s pharmaceutical market is very competitive.  Once dominated by two local domestic generic producers, Lek and Krka, the market is now increasingly open to competition from foreign competitors.  According to the Slovenian National Institute of Public Health, Slovenia spent approximately EUR 679.5 million on pharmaceuticals in 2022.  Each Slovenian spends an average of EUR 322 each year to purchase an average of 9 prescription medications.

The Ministry of Health is the primary actor in Slovenia’s pharmaceutical market.  The ministry develops healthcare policies, proposes the government’s healthcare budget, and monitors spending in the national healthcare fund, with an eye toward keeping medical costs as low as possible.  Slovenia has introduced therapeutic reference pricing schemes similar to those of other EU member states, which have made market conditions difficult for producers of brand-name pharmaceuticals. 

Experts forecast seven percent annual growth for the pharmaceutical market over the next two years, despite downward pressure on certain therapeutic products.  Almost three quarters of all pharmaceuticals approved for sale in Slovenia are imported, accounting for nearly 16 percent of total health care spending.  As of 2021, 73.7 percent of healthcare spending is publicly financed, and international comparisons show that drug consumption in Slovenia is higher than EU average and growing by 1.5 percent per year.  Increased life expectancies and the growth in private health care insurance are expected to have a positive impact on the market.

Slovenia’s premier research institution, the Jozef Stefan Institute, is closely involved in chemical and pharmaceutical research and development, including therapeutic nanotechnology and biotechnology products. 

Table: Total Market Size for Pharmaceuticals
Unit: USD millions2019202020212022
Total Local Production2,6662,7002,8843,527
Total Exports2,4502,5602,6792,900
Total Imports370400400450

Imports from the US

 

284290290310
Total Market Size560583605734
Exchange Rates1.081.081.0581.08

(Source: Statistical Office of Slovenia, National Institute of Public Health)

Leading Sub-Sectors

  • Drugs for cardiovascular illnesses
  • Branded products for cancer treatments
  • Pharmaceuticals for psychotherapy
  • AIDS medications
  • Supplements

Opportunities

The best prospects for American-made pharmaceutical companies are in the fields of cancer medications, cardiovascular medications, and bio-technologically-produced medications.

Resources

Ministry of Health, Štefanova 5, SI- 1000 Ljubljana, Slovenia

E-mail: gp.mz@gov.si  

Agency for Drugs and Medical Devices, Ptujska 21, 1000 Ljubljana, Slovenia

E-mail: info@jazmp.si 

National Institute of Public Health, Trubarjeva 2, 1000 Ljubljana, Slovenia

E-mail: info@nijz.si

Chamber of Commerce and Industry of Slovenia, Dimiceva 13, 1504 Ljubljana, Slovenia E-mail: info@gzs.si 

U.S. Commercial Service

Mirjana Rabič, Economic Commercial Specialist

Phone: +386 1 200 5500

Fax: +386 1 200 5555

E-mail: DoingBusinessinSlovenia@state.gov

×

Global Business Navigator Chatbot Beta

Welcome to the Global Business Navigator, an artificial intelligence (AI) Chatbot from the International Trade Administration (ITA). This tool, currently in beta version testing, is designed to provide general information on the exporting process and the resources available to assist new and experienced U.S. exporters. The Chatbot, developed using Microsoft’s Azure AI services, is trained on ITA’s export-related content and aims to quickly get users the information they need. The Chatbot is intended to make the benefits of exporting more accessible by understanding non-expert language, idiomatic expressions, and foreign languages.

Limitations

As a beta product, the Chatbot is currently being tested and its responses may occasionally produce inaccurate or incomplete information. The Chatbot is trained to decline out of scope or inappropriate requests. The Chatbot’s knowledge is limited to the public information on the Export Solutions web pages of Trade.gov, which covers a wide range of topics on exporting. While it cannot provide responses specific to a company’s product or a specific foreign market, its reference pages will guide you to other relevant government resources and market research. Always double-check the Chatbot’s responses using the provided references or by visiting the Export Solutions web pages on Trade.gov. Do not use its responses as legal or professional advice. Inaccurate advice from the Chatbot would not be a defense to violating any export rules or regulations.

Privacy

The Chatbot does not collect information about users and does not use the contents of users’ chat history to learn new information. All feedback is anonymous. Please do not enter personally identifiable information (PII), sensitive, or proprietary information into the Chatbot. Your conversations will not be connected to other interactions or accounts with ITA. Conversations with the Chatbot may be reviewed to help ITA improve the tool and address harmful, illegal, or otherwise inappropriate questions.

Translation

The Chatbot supports a wide range of languages. Because the Chatbot is trained in English and responses are translated, you should verify the translation. For example, the Chatbot may have difficulty with acronyms, abbreviations, and nuances in a language other than English.

Privacy Program | Information Quality Guidelines | Accessibility